{"groups":[{"description":"Participants received brentuximab vedotin 1.8 milligrams per kilogram (mg/kg), intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 milligrams per square meter (mg/m\\^2) and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurred first.","id":"FG000","title":"Brentuximab Vedotin + CHP"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to follow up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"46"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"52"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 52 participants with newly diagnosed CD30-positive (CD30+) peripheral T-cell lymphomas (PTCL) were enrolled in the study and treated with brentuximab vedotin in combination with cyclophosphamide, doxorubicin (hydroxydaunorubicin) and prednisone (CHP). The results presented are until the primary completion date.","recruitmentDetails":"Participants took part in the study at 14 investigative sites in China from 10 February 2023 to 27 April 2025. The study is ongoing."}